Karin Eastham CPA serves as Lead Independent Director of the Company. Ms. Eastham has served as a director of Geron since March 2009, and as Lead Independent Director of the Board since December 2018. Ms. Eastham also serves as a member of the boards of directors of Veracyte, Inc., a molecular diagnostics company, since December 2012; Nektar Therapeutics, a clinical-stage biopharmaceutical company, since September 2018, and Personalis, Inc., a diagnostic company developing genomic sequencing tools, since September 2019. Ms. Eastham previously served as a director of Illumina, Inc., a manufacturer of life science tools and reagents, from July 2004 to May 2019; MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company, from May 2012 to May 2017; Trius Therapeutics, Inc., a biopharmaceutical company, from 2009 until its sale in 2013; Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders, from 2005 until its sale in 2012; and Genoptix, Inc., a provider of specialized laboratory services, from 2008 until its sale in 2011. From 1976 until her retirement in September 2008, Ms. Eastham has held several senior management positions in finance in the biopharmaceutical industry, including with the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research; Diversa Corporation, a biotechnology company; CombiChem, Inc., a computational chemistry company; Cytel Corporation, a biopharmaceutical company; and Boehringer Mannheim Corporation, a biopharmaceutical company. Ms. Eastham holds a B.S. and an M.B.A. from Indiana University and is a retired Certified Public Accountant.
What is Karin Eastham's net worth?
The estimated net worth of Karin Eastham is at least $1.19 million as of July 16th, 2024. Ms. Eastham owns 33,228 shares of Veracyte stock worth more than $1,194,214 as of November 15th. This net worth evaluation does not reflect any other investments that Ms. Eastham may own. Learn More about Karin Eastham's net worth.
How do I contact Karin Eastham?
Has Karin Eastham been buying or selling shares of Veracyte?
Karin Eastham has not been actively trading shares of Veracyte during the last ninety days. Most recently, Karin Eastham sold 7,500 shares of the business's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $25.00, for a transaction totalling $187,500.00. Following the completion of the sale, the director now directly owns 33,228 shares of the company's stock, valued at $830,700. Learn More on Karin Eastham's trading history.
Who are Veracyte's active insiders?
Are insiders buying or selling shares of Veracyte?
In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 63,827 shares worth more than $1,779,423.17. The most recent insider tranaction occured on September, 19th when Director Evan/ Fa Jones sold 5,173 shares worth more than $182,244.79. Insiders at Veracyte own 1.3% of the company.
Learn More about insider trades at Veracyte. Information on this page was last updated on 9/19/2024.
